End-Stage Renal Disease (ESRD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

End-Stage Renal Disease (ESRD) Market Outlook

Thelansis’s “End-Stage Renal Disease (ESRD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential End-Stage Renal Disease (ESRD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

End-Stage Renal Disease (ESRD) Overview

End-stage renal disease (ESRD) is the irreversible stage of kidney impairment that cannot be controlled by conservative management alone and requires dialysis or kidney transplantation to maintain life. There are two levels of kidney impairment that can lead to ESRD: acute and chronic. End-stage renal disease (ESRD) implies chronic renal failure (CRF) of a degree (i.e., glomerular filtration rate, GFR<10–12 mL/min) such that life cannot be sustained long-term without dialysis. In contrast to acute kidney failure, chronic kidney failure is a permanent condition that leads to a progressive decline in renal function. Once it occurs, the kidneys cannot be made to function properly again, even when an inciting event has been corrected. CRF may exist for 10 to 20 years before progressing to ESRD. Over 70% of late-stage chronic kidney disease cases result from prolonged diabetes mellitus or hypertension. Glomerulonephritis, cystic diseases, and other urologic diseases account for another 12%, and 15% of patients have other or unknown causes of CRF. Long-term complications of chronic kidney disease (CKD) include a high risk of morbidity and mortality of cardiovascular disease compared to the general population. Mortality attributable to a cardiovascular cause accounts for 45% of all deaths of patients receiving dialysis. Between 80% and 90% of patients with CKD die of cardiovascular disease before reaching the need for dialysis. The precise biologic mechanisms for this are unclear. However, they may have to do with the uremic milieu, underlying coexistent comorbidities, and a hesitancy to perform investigative procedures in patients with chronic kidney disease.

• End-stage renal disease (ESRD) incidence varies from 351 to 421 cases per million population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: